Clinical Trial Update: Efficacy of 3,4-DAP in Fatigue Associated With Multiple Sclerosis [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating the efficacy of 3,4-DAP for fatigue in multiple sclerosis completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• 3,4-DAP (3,4-diaminopyridine)

Snippet

Sponsor: Assistance Publique - Hôpitaux de Paris | Conditions: Multiple Sclerosis | Phase 3 | Status: COMPLETED